LU81294A1 - Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci - Google Patents

Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci Download PDF

Info

Publication number
LU81294A1
LU81294A1 LU81294A LU81294A LU81294A1 LU 81294 A1 LU81294 A1 LU 81294A1 LU 81294 A LU81294 A LU 81294A LU 81294 A LU81294 A LU 81294A LU 81294 A1 LU81294 A1 LU 81294A1
Authority
LU
Luxembourg
Prior art keywords
naltrexone
fenfluramine
anorexia
dose
appetite
Prior art date
Application number
LU81294A
Other languages
English (en)
French (fr)
Inventor
D Smith Jr
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of LU81294A1 publication Critical patent/LU81294A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU81294A 1978-05-19 1979-05-18 Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci LU81294A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90782578A 1978-05-19 1978-05-19
US90782578 1978-05-19
US06/027,270 US4217353A (en) 1978-05-19 1979-04-06 Method for inducing anorexia
US2727079 1979-04-06

Publications (1)

Publication Number Publication Date
LU81294A1 true LU81294A1 (fr) 1980-06-05

Family

ID=26702250

Family Applications (1)

Application Number Title Priority Date Filing Date
LU81294A LU81294A1 (fr) 1978-05-19 1979-05-18 Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci

Country Status (10)

Country Link
US (1) US4217353A (fi)
EP (1) EP0005636A1 (fi)
AU (1) AU526854B2 (fi)
DK (1) DK205979A (fi)
FI (1) FI791591A (fi)
GR (1) GR68440B (fi)
IT (1) IT7922846A0 (fi)
LU (1) LU81294A1 (fi)
PH (1) PH15271A (fi)
PT (1) PT69628B (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477457A (en) * 1982-10-28 1984-10-16 E. I. Du Pont De Nemours And Company Method for inducing anorexia using nalmetrene
HU201675B (en) * 1983-08-26 1990-12-28 Ivan Balkanyi Process for producing oral pharmaceutical compositions with unappetizing effect
US4478840A (en) * 1983-10-11 1984-10-23 E. I. Du Pont De Nemours And Company Appetite suppressing compositions and methods
US4600718A (en) * 1984-09-18 1986-07-15 Huebner Hans F Method of treating weight loss disorders
US4546103A (en) * 1984-09-18 1985-10-08 Huebner Hans F Method of treating weight loss disorders
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US4912114A (en) * 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
ES2069272T3 (es) * 1989-11-27 1995-05-01 Fisons Corp Hexapeptidos con grupos esteres sulfato.
DK0547151T3 (da) * 1990-08-29 2003-03-17 Humanetics Corp Behandlingsmåde til fremme af vægttab under anvendelse af et substitueret delta-5-androsten
EP0828489A4 (en) * 1996-03-13 2001-04-04 Univ Yale Smoking cessation treatment using naltrexone and related compounds
US20040167164A1 (en) * 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6846831B2 (en) * 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US7501433B2 (en) 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
SI2316456T1 (sl) * 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7910599B2 (en) 2005-01-10 2011-03-22 John David Sinclair Method for treating eating disorders by selective extinction with transdermal naloxone
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20160072276A (ko) 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives

Also Published As

Publication number Publication date
DK205979A (da) 1979-11-20
IT7922846A0 (it) 1979-05-18
US4217353A (en) 1980-08-12
PT69628B (pt) 1981-10-21
PT69628A (fr) 1979-06-01
AU4714379A (en) 1979-11-22
EP0005636A1 (en) 1979-11-28
FI791591A (fi) 1979-11-20
AU526854B2 (en) 1983-02-03
GR68440B (fi) 1981-12-30
PH15271A (en) 1982-11-02

Similar Documents

Publication Publication Date Title
LU81294A1 (fr) Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci
Blackwell Adverse effects of antidepressant drugs: part 1: monoamine oxidase inhibitors and tricyclics
EP3941904A1 (en) Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
TW522012B (en) Denaturants for sympathomimetic amine salts
JP2002538106A (ja) イソバレルアミド、イソ吉草酸、または関連化合物を用いてｃｎｓ活性の調節に影響を与えることによる、痙縮および痙攣を含む様々な病状の治療
WO2006053186A2 (en) Method for treatment of movement disorders
JP2002538106A5 (fi)
HUE035105T2 (en) A composition comprising nicotine and opipramole and its use
WO2022115798A2 (en) Compositions and methods for treating migraine
RU2232016C2 (ru) Изовалерамид-антиспастическое и противосудорожное средство, экстракт из растения семейства valerianaceae или хмеля - средство для лечения симптома спастичности и способ устранения этого симптома, способ лечения патологии, снимаемой центрально-опосредованным снижением мышечного тонуса
BE898540A (fr) Procédé pour soulager les troubles moteurs extrapyramidaux.
Jones et al. Why do cholestatic patients itch?
JPS59501459A (ja) カフェインを含んで成る改良された鎮痛及び抗炎症組成物並びにその使用方法
US5998473A (en) Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester derivatives
Bania et al. Gamma‐hydroxybutyric acid tolerance and withdrawal in a rat model
RU2423981C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона
BE876382A (fr) Procede pour causer de l'anorexie par administration buccale de naltrexone ou d'un sel de celle-ci
TW202308653A (zh) 以神經活性類固醇進行治療的方法
RU2461374C1 (ru) Биологически активное средство, влияющее на общеметаболические, возбуждающие и тормозные функции нервной системы и интеллектуально-мнестические функции головного мозга (варианты)
CN118806909A (zh) 乙酰胆碱酯酶抑制剂和艾达鲁吡啶用于减少帕金森氏病患者跌倒的用途
US6326400B1 (en) N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement
WO2012175894A1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
Yadav Pharmacology & Toxicology
FR3017296A1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
CH640137A5 (fr) Composition pharmaceutique contenant de la s-adenosyl-l-homocysteine.